# EU-1-22-1697_public-assessment-report_20221212_20221212_teriparatide-sun-epar-public-assessment-report.pdf

EUROPEAN MEDICINES AGENCY
SCIENCE
MEDICINES
HEALTH
15 September 2022
EMA/897619/2022
Committee for Medicinal Products for Human Use (CHMP)
Assessment report
Teriparatide SUN
International non-proprietary name: teriparatide
Procedure No. EMEA/H/C/005793/0000
Note
Assessment report as adopted by the CHMP with all information of a commercially confidential nature
deleted.
Official address Domenico Scarlattilaan 6 . 1083 HS Amsterdam . The Netherlands
Address for visits and deliveries Refer to www.ema.europa.eu/how-to-find-us
Send us a question Go to www.ema.europa.eu/contact Telephone +31 (0)88 781 6000
An agency of the European Union
C European Medicines Agency, 2022. Reproduction is authorised provided the source is acknowledged.
Administrative information
Name of the medicinal product:
Teriparatide SUN
Applicant:
Sun Pharmaceutical Industries Europe B.V.
Polarisavenue 87
2132JH Hoofddorp
NETHERLANDS
Active substance:
Teriparatide
International Nonproprietary
Name/Common Name:
teriparatide
Pharmaco-therapeutic group
(ATC Code):
PARATHYROID HORMONES AND ANALOGUES,
Parathyroid hormones and analogues
(H05AA02)
Therapeutic indication(s):
Teriparatide SUN is indicated in adults.
Treatment of osteoporosis in postmenopausal
women and in men at increased risk of
fracture (see section 5.1). In postmenopausal
women, a significant reduction in the
incidence of vertebral and non- vertebral
fractures but not hip fractures has been
demonstrated.
Pharmaceutical form(s):
Solution for injection
Strength(s):
20 ug/80 ul
Route(s) of administration:
Subcutaneous use
Treatment of osteoporosis associated with
sustained systemic glucocorticoid therapy in
women and men at increased risk for fracture
(see section 5.1).
Assessment report
EMA/897619/2022
Page 2/36
